Omiloxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Omiloxetine
Omiloxetine.svg
Systematic (IUPAC) name
2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone
Clinical data
Legal status ?
Identifiers
CAS number 176894-09-0
ATC code None
PubChem CID 3047803
ChemSpider 2310120
Chemical data
Formula C27H25F2NO4 
Mol. mass 465.489 g/mol

Omiloxetine (INN) is an antidepressant with a similar chemical structure to that of paroxetine which either was or is still under development by Ferrer Internacional for the treatment of major depression.[1][2] It acts as a highly selective serotonin reuptake inhibitor (SSRI), and is said to possess a greater degree of selectivity for serotonin reuptake over dopamine and norepinephrine reuptake compared to other SSRIs.[2] Though omiloxetine is listed as still under development on Ferrer's website, there has been no new news on the drug since late 2005.[3]

References[edit]

  1. ^ "Ferrer Grupo - Pharmaceutical - R&D&I". Retrieved 2012-05-19. 
  2. ^ a b De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19. 
  3. ^ Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19.